10x Genomics (MEX:TXG) ROCE % : -17.46% (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is 10x Genomics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. 10x Genomics's annualized ROCE % for the quarter that ended in Sep. 2024 was -17.46%.

10x Genomics ROCE % Historical Data

The historical data trend for 10x Genomics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

10x Genomics ROCE % Chart

10x Genomics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-8.75

-80.37

-6.24

-17.42

-26.61

10x Genomics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial															-42.64	-21.87	-27.67	-19.06	-17.46

10x Genomics ROCE % Calculation

10x Genomics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-4222.005	/	( ( (20060.994 - 2553.138)	+	(16382.577 - 2158.479) )	/ 2 )
	=	-4222.005	/	( (17507.856	+	14224.098)	/ 2 )
	=	-4222.005	/	15865.977
	=	-26.61 %

10x Genomics's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	-2712.22	/	( ( (17031.614 - 2033.88)	+	(18465.445 - 2387.154) )	/ 2 )
	=	-2712.22	/	( ( 14997.734	+	16078.291 )	/ 2 )
	=	-2712.22	/	15538.0125
	=	-17.46 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

10x Genomics (MEX:TXG) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

10x Genomics ROCE % Related Terms

Thank you for viewing the detailed overview of 10x Genomics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

10x Genomics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » 10x Genomics Inc (MEX:TXG) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

TXG:USA 0A88:UK 1KJ:Germany

Address

6230 Stoneridge Mall Road, Pleasanton, CA, USA, 94588

Website

https://www.10xgenomics.com

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.